Rigel Pharmaceuticals Inc (RIGL.OQ)
10 Dec 2013
|Market Cap (Mil.):||$225.57|
|Shares Outstanding (Mil.):||87.43|
- Rigel Pharmaceuticals Inc said it would stop the development of its drug to treat skin lesions in patients with discoid lupus, a chronic skin disease, after the treatment failed a mid-stage trial.
* Two late-stage trials of blood disorder drug to start in 2014
Oct 24 - Rigel Pharmaceuticals Inc said it would stop the development of its drug to treat skin lesions in patients with discoid lupus, a chronic skin disease, after the treatment failed a mid-stage study.
* Rigel to review drug pipeline, discuss plans in 'near-term'
Aug 26 - Rigel Pharmaceuticals Inc said it will stop developing its experimental asthma drug after the therapy failed to improve the lung function of patients in a mid-stage trial.
|Novartis AG (NOVN.VX)||CHF69.15||-0.75|
|Merck & Co., Inc. (MRK.N)||$49.43||-0.13|
|Roche Holding Ltd. (ROG.VX)||CHF239.00||-4.00|
|Abbott Laboratories (ABT.N)||$37.11||-0.09|
|Bayer AG (BAYGn.DE)||€95.76||-1.22|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€72.81||-0.85|
|AstraZeneca plc (AZN.L)||3,450.00p||-24.50|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Rigel Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: New Constructs, LLC